Rheumatoid and psoriatic arthritis Musculoskeletal Diseases Rheumatoid arthritis
Conditions
Interventions
1. Demorgaphics (age, gender, living status, ethnicity) and clinical data (date of diagnosis, methotrexate start date, number of previous disease modifying anti-rheumatic drugs) will be collected at b
Sponsors
Joint UCLH and UCL Biomedical Research Unit (United Kingdom)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. All patients with a diagnosis of Rheumatoid or Psoriatic arthritis 2. Aged 18 years or over 3. Fluency in written and spoken English 4. Patients whose treatment is classified as stable defined as those who have had disease management with methotrexate for at least 6 months, plus a further 6 months if the patient is receiving a self-injected anti-TNF agent (Adaliumab or Etanercept)
Exclusion criteria
Exclusion criteria: 1. Identifiable psychosis or dementia 2. Significant co-morbidity (i.e. their predominant treatment is for another illness) 3. Those whose blood tests are being monitored by their GP
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The self management role and responsibility subscale of the Medication Education Impact Questionnaire, measured at baseline and again after the 3rd and 6th blood tests. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Impact of Methotrexate assessed by Medication Impact Questionnaire at baseline and after 3rd and 6th blood test 2. Knowledge about Methotrexate assessed by Methotrexate in Rheumatoid Arthritis Knowledge at baseline and after 3rd and 6th blood test 3. Impact of arthritis assessed by Health Education Impact Questionnaire at baseline and after 3rd and 6th blood test 4. Mood, anxiety and depression assessed by Hospital Anxiety and Depression Scale (HADS) at baseline and after 3rd and 6th blood test 5. Beliefs about arthritis assessed by Illness Perceptions Questionnaire Revised at baseline and after 3rd and 6th blood test 6. Social support at baseline and after 3rd and 6th blood test 7. Generalised Self Efficacy at baseline and after 3rd and 6th blood test 8. Beliefs about Methotrexate assessed by Beliefs about Medication Questionnaire at baseline and after 3rd and 6th blood test 9. Healthcare utilisation assessed by Treatment Burden (1-item measure) at baseline and after 3rd and 6th blood test 10. Self-reported adherence to Methotrexate Medication Adherence Report Scale at baseline and after 3rd and 6th blood test 11. Functional disability assessed by Health Assessment Questionnaire-II at baseline and after 3rd and 6th blood test 12. Pain in last 2 weeks assessed by Pain Visual Analogue Scale (VAS) (0-10) at baseline and after 3rd and 6th blood test 13. Fatigue in last 2 weeks assessed by Fatigue VAS (0-10) at baseline and after 3rd and 6th blood test 14. Disease activity (RA & PsA) assessed by Disease Acitivity Score in Rheumatoid Arthirtis-28 & Psoriatic Arthritis Response Criteria at baseline and after 6th blood test | — |
Countries
United Kingdom
Outcome results
None listed